Eliquis and Synjardy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eliquis (apixaban) and Synjardy (empagliflozin; metformin hydrochloride). Common drug interactions include headache among females and arthralgia among males.

The phase IV clinical study analyzes what interactions people have when they take Eliquis and Synjardy. It is created by eHealthMe based on reports of 64 people who take the same drugs from the FDA, and is updated regularly.

What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 191,861 Eliquis users. Check the latest studies of Eliquis.

What is Synjardy?

Synjardy has active ingredients of empagliflozin; metformin hydrochloride. eHealthMe is studying from 2,928 Synjardy users. Check the latest studies of Synjardy.



On Aug, 12, 2026

64 people who take Eliquis and Synjardy together, and have interactions are studied.

Eliquis and Synjardy drug interactions.

What are the common drug interactions of Eliquis and Synjardy, by gender? *:

female:

  1. Headache (pain in head)
  2. Initial insomnia (feeling of inadequate or poor-quality sleep)
  3. Insomnia (sleeplessness)
  4. Kidney infection
  5. Loss of consciousness
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Mastoiditis (infection of mastoid bone)
  8. Muscle spasms (muscle contraction)
  9. Neuropathy peripheral (surface nerve damage)
  10. Oropharyngeal discomfort (pain or irritation of oropharynx)

male:

  1. Arthralgia (joint pain)
  2. Pain in extremity
  3. Blood pressure increased
  4. Dizziness
  5. Hypotension (abnormally low blood pressure)
  6. Loss of consciousness
  7. Lyme disease (a bacterial infection that is spread to humans by infected ticks)
  8. Myopathy (a muscular disease in which the muscle fibres do not function)
  9. Myositis (inflammation of the muscles)
  10. Psoriasis (immune-mediated disease that affects the skin)

What are the common drug interactions of Eliquis and Synjardy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Arthralgia (joint pain)
  2. Pain in extremity
  3. Gait disturbance
  4. Joint range of motion decreased (disease of joint movement)
  5. Ligament sprain (ligament stretched)
  6. Blood glucose increased
  7. Device failure

50-59:

  1. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  2. Cushing's syndrome (obesity, a rounded face, increased fat)
  3. Exostosis (formation of new bone on the surface of a bone)
  4. Nasopharyngitis (inflammation of the nasopharynx)
  5. Platelet count decreased
  6. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
  7. Hyperglycaemia (high blood sugar)
  8. Hypotension (abnormally low blood pressure)
  9. Impaired healing
  10. Mastication disorder (disease of chewing food)

60+:

  1. Fatigue (feeling of tiredness)
  2. Blood pressure increased
  3. Glycosylated haemoglobin increased
  4. Lactic acidosis (low ph in body tissues)
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Urinary tract infection
  7. Alopecia (absence of hair from areas of the body)
  8. Glossitis (infection of tongue with soreness)
  9. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
  10. Rash

What are the existing conditions these people have? *

  1. Type 2 Diabetes: 11 people, 17.19%
  2. Multiple Myeloma (cancer of the plasma cells): 9 people, 14.06%
  3. High Blood Pressure: 8 people, 12.50%
  4. Diabetes: 6 people, 9.38%
  5. Renal Cell Carcinoma (a kidney cancer): 5 people, 7.81%
  6. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 6.25%
  7. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Eliquis and Synjardy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Eliquis and Synjardy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Eliquis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Synjardy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Eliquis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Synjardy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on apixaban and empagliflozin; metformin hydrochloride (the active ingredients of Eliquis and Synjardy, respectively), and Eliquis and Synjardy (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: